Home Stock The rare blood clot associated with J&J's COVID-19 injection is similar to...

The rare blood clot associated with J&J’s COVID-19 injection is similar to problems with the AstraZeneca vaccine, FDA official said.


The rare blood clots reported in six people who received Johnson & Johnson’s COVID-19 vaccine were similar to clots detected in very small numbers, federal health officials said. Europe was vaccinated with the AstraZeneca shot.

USA on Tuesday offer to pause vaccination with J&J vaccines until more information on how to treat the clotting disorder.

J & J’s
JNJ,
-1.34%

stocks fell 1.3 percent in after-hours trading on Tuesday, with analysts at SVB Leerink noting that the “pause” had reduced stocks.

Health officials said Tuesday they are reviewing vaccine data to better understand why blood clots occur and the Centers for Disease Control and Prevention’s Immunization Practice Advisory Committee The disease is expected to hold emergency meeting discuss J&J vaccines on Wednesday afternoon. Six cases in the US are in women between the ages of 18 and 48.

Similar analysts at SVB Leerink predict the commission will update its recommendations to say that women under 50 should no longer be vaccinated.

Women are disproportionately affected by this condition, both with the J&J vaccine as well as with AstraZeneca
AZN,
-0.47%

in Europe.

“If someone has this really rare syndrome … the most common way to treat it is with heparin,” Dr. Anthony Fauci, President Joe Biden’s chief medical advisor, said in an interview. briefings at the White House. “It would be a mistake in this situation because it could be dangerous and make the situation much worse. So there’s a clinically relevant reason why you want to make this known to everyone. “

Officials say the condition cited by Fauci is severe – one has died in the US, and another is in serious condition, officials said – and is also very rare, occurring in about 1. out of 1 million people who have injected Johnson & Johnson.

A coagulation disorder is called cerebral venous sinus thrombosis, and it has only been reported in people who also have low blood platelet counts, a condition known as thrombocytopenia.

“What’s really remarkable here is not just cerebral sinus thrombosis or thrombocytopenia,” said Dr. Peter Marks, director of the Center for Biological Research and Evaluation of the Food and Drug Administration, said in a private press conference. “Two things can happen. It was their appearance together that created a pattern, and that pattern was very, very similar to what was seen in Europe. “

AstraZeneca’s vaccine, developed in partnership with Oxford University, is authorized in the UK and Europe, where health regulators in a number of countries have stopped using vaccines due to Rare reports of blood clots, mainly in women and occurs in the first weeks after vaccination. This is similar to the reports that have emerged in the US

Vaccines Johnson & Johnson and AstraZeneca COVID-19 are both adenovirus vector-based vaccines. J&J’s shot was authorized in the US in February and in the European Union in mid-March, although the company said it now plans to delay the vaccine rollout in Europe.

“It is a similar mechanism that could happen with other adeno virus vector vaccines,” added Marks. “That is, this is an immune response that happens very rarely in vaccinated people, and that immune response leads to the activation of these extremely rare platelets and blood clots.”

No cases of thrombotic syndrome have been reported in people who took Pfizer Inc.
PFE,
+ 0.51%

or Moderna Inc.
MRNA,
+ 7.40%

vaccine mRNA, although there have been concerns about it earlier Allergic reactions occur in people who receive those injections.

Shares of J&J have risen 1.3% this year, while US-listed AstraZeneca shares are down 1.6%. The S&P 500 is wider
SPX,
+ 0.33%

up 9.9% for the year.

But related story:

Johnson & Johnson vaccine interruptions: What you need to know if you’ve already had or scheduled an injection

The Johnson & Johnson pause ‘will have no significant impact on our vaccination plan,’ said the White House

Shares Moderna, BioNTech rose after regulators stopped using J&J vaccines

The US COVID vaccine program faces failure with J&J jab, as experts argue there is no reason to alarm

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments